Black Titan (BTTC) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Key Stats

• Today's Range: $1.23 to $1.29
• 50-Day Range: $1.22 to $1.55
• 52-Week Range: $1.21 to $39.00
• Volume: 16,175 shs
• Average Volume: 879,199 shs
• Market Capitalization: $13.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Black Titan Stock Analysis - MarketRank™

Black Titan scored higher than 20% of companies evaluated by MarketBeat, and ranked 42nd out of 54 stocks in the services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Black Titan has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Black Titan has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Black Titan is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Black Titan is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Black Titan has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Black Titan has been sold short.

Short Interest Ratio / Days to Cover

Black Titan has a short interest ratio ("days to cover") of 0.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Black Titan has recently decreased by 21.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Black Titan does not currently pay a dividend.

Dividend Growth

Black Titan does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

Black Titan has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Services companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Black Titan this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for BTTC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Black Titan to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Black Titan insiders have not sold or bought any company stock.

Percentage Held by Insiders

53.70% of the stock of Black Titan is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Black Titan has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/18/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Services
• Industry: Services – Computer Programming And Data Processing
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:BTTC
• CIK: 2034400
• Web: www.titanpharm.com
• Phone: 6012-484 4444
• Fax: 650-244-4956
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $180 thousand
• Price / Sales: 75.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 10,770,000
• Free Float: 4,627,000
• Market Cap: $13.57 million
• Optionable: N/A
• Beta: 1.28